Cargando…

Nanoemulsions as Gene Delivery in Mucopolysaccharidosis Type I—A Mini-Review

Mucopolysaccharidosis type I (MPS I) is a rare monogenic disease in which glycosaminoglycans’ abnormal metabolism leads to the storage of heparan sulfate and dermatan sulfate in various tissues. It causes its damage and impairment. Patients with the severe form of MPS I usually do not live up to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zapolnik, Paweł, Pyrkosz, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103791/ https://www.ncbi.nlm.nih.gov/pubmed/35563175 http://dx.doi.org/10.3390/ijms23094785

Ejemplares similares

Gene Therapy for Mucopolysaccharidosis Type II—A Review of the Current Possibilities
por: Zapolnik, Paweł, et al.
Publicado: (2021)

RNF6 as an Oncogene and Potential Therapeutic Target—A Review
por: Zapolnik, Paweł, et al.
Publicado: (2020)

Mucopolysaccharidosis Type I
por: Kubaski, Francyne, et al.
Publicado: (2020)

Factors influencing transfection efficiency of pIDUA/nanoemulsion complexes in a mucopolysaccharidosis type I murine model
por: Fraga, Michelle, et al.
Publicado: (2017)

Open issues in Mucopolysaccharidosis type I-Hurler
por: Parini, Rossella, et al.
Publicado: (2017)

Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology
por: Hampe, Christiane S., et al.
Publicado: (2020)

α-L-iduronidase therapy for mucopolysaccharidosis type I
por: Tolar, Jakub, et al.
Publicado: (2008)

Mucopolysaccharidosis Type I in Mexico: Case-Based Review
por: Cantú-Reyna, Consuelo, et al.
Publicado: (2023)

Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement
por: Hampe, Christiane S., et al.
Publicado: (2021)

Techniques for Formulation of Nanoemulsion Drug Delivery System: A Review
por: Kumar, Manish, et al.
Publicado: (2019)

Microemulsions and Nanoemulsions in Skin Drug Delivery
por: Souto, Eliana B., et al.
Publicado: (2022)

Nanoemulsions for “Nose-to-Brain” Drug Delivery
por: Bonferoni, Maria Cristina, et al.
Publicado: (2019)

Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment
por: Giugliani, Roberto, et al.
Publicado: (2010)

Phenotype prediction for mucopolysaccharidosis type I by in silico analysis
por: Ou, Li, et al.
Publicado: (2017)

Molecular Analysis of Vietnamese Patients with Mucopolysaccharidosis Type I
por: Can, Ngoc Thi Bich, et al.
Publicado: (2021)

Intravenous delivery for treatment of mucopolysaccharidosis type I: A comparison of AAV serotypes 9 and rh10
por: Belur, Lalitha R., et al.
Publicado: (2020)

Mucopolysaccharidosis: A broad review
por: Nagpal, Ritu, et al.
Publicado: (2022)

Novel therapies for mucopolysaccharidosis type III
por: Seker Yilmaz, Berna, et al.
Publicado: (2020)

Nanoemulsion: an advanced mode of drug delivery system
por: Jaiswal, Manjit, et al.
Publicado: (2014)

Mucopolysaccharidosis Type VI, an Updated Overview of the Disease
por: D’Avanzo, Francesca, et al.
Publicado: (2021)

Mucopolysaccharidosis VI
por: Valayannopoulos, Vassili, et al.
Publicado: (2010)

Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I)
por: Barbosa Mendes, Ana, et al.
Publicado: (2019)

Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB
por: Wilkinson, Fiona L., et al.
Publicado: (2012)

Cardiac abnormalities in adults with the attenuated form of mucopolysaccharidosis type I
por: Soliman, O. I. I., et al.
Publicado: (2007)

Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I
por: Lund, Troy C., et al.
Publicado: (2020)

Mucopolysaccharidosis Type I Diagnosed by Aortic and Mitral Valve Replacement
por: Sherwood, Dalton J., et al.
Publicado: (2021)

Cellular and Gene Expression Response to the Combination of Genistein and Kaempferol in the Treatment of Mucopolysaccharidosis Type I
por: Węsierska, Magdalena, et al.
Publicado: (2022)

Mucopolysaccharidosis type IIIB: a current review and exploration of the AAV therapy landscape
por: Rouse, Courtney J., et al.
Publicado: (2023)

A pilot newborn screening program for Mucopolysaccharidosis type I in Taiwan
por: Lin, Shuan-Pei, et al.
Publicado: (2013)

Case Report: Cerebral Revascularization in a Child With Mucopolysaccharidosis Type I
por: Grant, Nathan, et al.
Publicado: (2021)

Report of Five Years of Experience in Neonatal Screening for Mucopolysaccharidosis Type I and Review of the Literature
por: Gragnaniello, Vincenza, et al.
Publicado: (2020)

Airway Abnormalities in Adult Mucopolysaccharidosis and Development of Salford Mucopolysaccharidosis Airway Score
por: Gadepalli, Chaitanya, et al.
Publicado: (2021)

Lentiviral-mediated gene correction of mucopolysaccharidosis type IIIA
por: Anson, Donald S, et al.
Publicado: (2007)

Osteoarthropathy in mucopolysaccharidosis type II
por: NASCU, IOANA, et al.
Publicado: (2013)

Mucopolysaccharidosis-Plus Syndrome
por: Vasilev, Filipp, et al.
Publicado: (2020)

Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2017)

Mucopolysaccharidosis type I Hurler-Scheie syndrome affecting two sisters
por: Anand, Reena, et al.
Publicado: (2015)

Clinical and Molecular Characterization of Patients with Mucopolysaccharidosis Type I in an Algerian Series
por: Tebani, Abdellah, et al.
Publicado: (2016)

Mutation analysis and clinical characterization of Iranian patients with mucopolysaccharidosis type I
por: Taghikhani, Mohammad, et al.
Publicado: (2019)

Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I
por: Giugliani, Roberto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rq8r19jgvekkk3q7omgoglkh2a